Skip to main content

Table 5 Direct medical costs (USD) for 3 years among dapagliflozin treated patients and DPP-4i treated patients

From: Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study

Patient groups

Treatment

Treatment year

Total

1st year

2nd year

3rd year

Base analysis

 All patients

Dapagliflozin

832,312

847,560

862,349

2,542,221

DPP-4i

844,608

870,883

884,517

2,600,008

Difference

12,296

23,323

22,169

57,787

 Patients with underlying CVD

Dapagliflozin

1,334,443

1,376,727

1,417,845

4,129,014

DPP-4i

1,373,319

1,448,896

1,484,380

4,306,594

Difference

38,876

72,169

66,535

177,580

 Patients without underlying CVD

Dapagliflozin

755,451

764,393

772,895

2,292,739

DPP-4i

760,709

774,577

782,840

2,318,126

Difference

5258

10,184

9945

25,387

Sensitivity analysis

 All patients

Dapagliflozin

838,482

859,691

880,237

2,578,409

DPP-4i

848,827

879,127

898,553

2,626,506

Difference

10,345

19,436

18,317

48,097

 Patients with underlying CVD

Dapagliflozin

1,347,676

1,402,655

1,455,945

4,206,275

DPP-4i

1,379,600

1,460,981

1,508,597

4,349,179

Difference

31,925

58,327

52,653

142,904

 Patients without underlying CVD

Dapagliflozin

759,669

772,623

784,938

2,317,229

DPP-4i

764,829

782,650

794,789

2,342,268

Difference

5160

10,027

9851

25,039

  1. DPP-4i Dipeptidyl-peptidase 4 inhibitor, CVD cardiovascular disease